CURIS INC

Listed Company

CRISCIK 0001108205NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

$9.44M

Net Income

$-7.60M

Total Assets

$19.97M

Equity

$5.46M

Shares Out

39.98M

Op. Cash Flow

$-27.20M

Business

CURIS INC is a biotechnology company focused on discovery and development of small molecule therapeutics, principally the IRAK4 inhibitor emavusertib. Its main products and programs include emavusertib (clinical development in hematologic malignancies and CNS lymphoma), outlicensed Erivedge and partnered programs such as CA-170 and CA-327, plus other preclinical candidates. The company operates in a single reporting segment centered on drug discovery, clinical development and collaborations, with multiple license and collaboration arrangements (e.g., Aurigene, Genentech). CURIS conducts clinical trials and regulatory interactions across the United States and Europe and relies on third‑party manufacturers, collaborators and global partners for development, commercialization and distribution.

Summary from filing dated 2025-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenues, net	9	11	10	10	11
Cost of royalties	45,000	98,000	212,000	300,000	500,000
Research and development	28	39	39	43	35
General and administrative	14	17	19	20	17
Total operating expenses	42	55	58	63	53
Gain on release of liability related to sale of future royalties associated with sale of assets	27	0	—	—	—
Loss from operations	−6	−45	−48	−53	−42
Interest income	316,000	2	3	1	211,000
Expense related to the sale of future royalties	−2	−615,000	−2	−5	−4
Total other income (expense)	−2	1	919,000	−4	−3
Net loss	−8	−43	−47	−57	−45
Net loss per common share, basic (in dollars per share)	−0.58	−6.88	−8.96	−12.14	0.5
Net loss per common share, diluted (in dollars per share)	−0.58	−6.88	−8.96	−12.14	0.5
Weighted average common shares, basic (in shares)	13	6	5	5	92
Weighted average common shares, diluted (in shares)	13	6	5	5	92
Unrealized gain (loss) on marketable securities	0	−229,000	415,000	−77,000	−106,000
Comprehensive loss	−8	−44	−47	−57	−46

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	5	20	27	20	40
Accounts receivable	0	3	3	3	3
Prepaid expenses and other current assets	2	3	2	4	3
Total current assets	7	26	61	92	122
Property and equipment, net	62,000	231,000	434,000	689,000	505,000
Restricted cash, long-term	544,000	544,000	544,000	635,000	726,000
Operating lease right-of-use asset	2	3	3	4	6
Other assets	2	2	3	2	0
Goodwill	9	9	9	9	9
Total assets	20	41	77	109	162
Accounts payable	6	3	3	3	6
Accrued liabilities	7	7	9	6	6
Current portion of operating lease liability	1	1	1	1	682,000
Current portion of liability related to sale of future royalties	0	8	9	—	0
Total current liabilities	14	19	22	10	13
Long-term operating lease liability	428,000	2	1	3	4
Liability related to the sale of future royalties, net	0	27	34	49	54
Total liabilities	15	47	58	62	72
Commitments and contingencies, Note 6	—	—	—	—	—
Preferred stock, $0.01 par value 5,000,000 shares authorized, no shares issued and outstanding at December 31, 2025 and 2024	0	0	0	0	—
Common stock, $0.01 par value68,343,750 shares authorized, 12,928,853 shares issued and outstanding at December 31, 2025; 34,171,875 shares authorized, 8,487,818 shares issued and outstanding at December 31, 2024	129,000	85,000	59,000	48,000	916,000
Additional paid-in capital	1,253	1,234	1,216	1,196	1,182
Accumulated deficit	−1,200	−1,240	−1,196	−1,149	−1,092
Total stockholders equity (deficit)	5	−6	20	47	91
Total liabilities and stockholders equity (deficit)	20	41	77	109	162

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	200,000	200,000	300,000	200,000	200,000
Non-cash lease expense	1	1	1	1	828,000
Stock-based compensation expense	4	6	6	7	5
Non-cash activity related to the sale of future royalties prior to the sale of Erivedge	360,000	154,000	−340,000	659,000	36,000
Amortization of premiums and discounts on investments	0	−16,000	−1	351,000	1
Accounts receivable	−1	−555,000	181,000	249,000	−181,000
Prepaid expenses and other assets	2	139,000	405,000	−2	−2
Accounts payable and accrued and other liabilities	3	−2	3	−4	5
Operating lease liability	−1	−1	−1	−907,000	−2
Total adjustments	−20	4	9	2	8
Net cash used in operating activities	−27	−40	−38	−54	−38
Purchases of investments	0	−18	−70	−62	−93
Sales and maturities of investments	0	48	108	95	45
Proceeds from the sale of Erivedge	3	0	—	—	—
Net cash provided by investing activities	3	29	38	33	−48
Proceeds from issuance of common stock, pre-funded warrants, and common warrants, net of issuance costs	15	12	14	6	0
Payment of liability of future royalties, net of imputed interest	−6	−9	−7	−5	−4
Net cash provided by financing activities	10	3	8	867,000	−4
Net decrease in cash and cash equivalents and restricted cash	−15	−7	7	−20	−90
Issuance costs in accounts payable	328,000	50,000	0	—	0
Cash paid for interest	2	461,000	2	4	4
Increase in right-of-use assets and operating lease liabilities resulting from lease modification	0	−1	0	191,000	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro